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Abstract
Background
Japanese encephalitis (JE) virus (JEV) is a mosquito-borne flavivirus found across Asia
that is closely related to West Nile virus. There is no known antiviral treatment for any flavivi-
rus. Results from in vitro studies and animal models suggest intravenous immunoglobulin
(IVIG) containing virus-specific neutralizing antibody may be effective in improving outcome
in viral encephalitis. IVIG’s anti-inflammatory properties may also be beneficial.
Methodology/Principal Findings
We performed a pilot feasibility randomized double-blind placebo-controlled trial of IVIG
containing anti-JEV neutralizing antibody (ImmunoRel, 400mg/kg/day for 5 days) in children
with suspected JE at two sites in Nepal; we also examined the effect on serum neutralizing
antibody titre and cytokine profiles. 22 children were recruited, 13 of whom had confirmed
JE; 11 received IVIG and 11 placebo, with no protocol violations. One child (IVIG group)
died during treatment and two (placebo) subsequently following hospital discharge. Overall,
there was no difference in outcome between treatment groups at discharge or follow up.
Passive transfer of anti-JEV antibody was seen in JEV negative children. JEV positive
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children treated with IVIG had JEV-specific neutralizing antibody titres approximately 16
times higher than those treated with placebo (p=0.2), which was more than could be ex-
plained by passive transfer alone. IL-4 and IL-6 were higher in the IVIG group.
Conclusions/Significance
A trial of IVIG for JE in Nepal is feasible. IVIG may augment the development of neutralizing
antibodies in JEV positive patients. IVIG appears an appealing option for JE treatment that
warrants further study.
Trial Registration
ClinicalTrials.gov NCT01856205
Introduction
Japanese encephalitis virus (JEV) infection is the most important cause of epidemic encephali-
tis worldwide, with over 60,000 cases annually [1]. JEV is found in Southeast Asia, China, the
Pacific Rim and the Asian subcontinent, and its geographical range is expanding [2]. JEV is a
small single-stranded positive-sense RNA flavivirus, closely related to West Nile virus (WNV)
that is transmitted between its natural bird and pig hosts by Culex tritaeniorhynchus and other
mosquitoes. JEV transmission occurs mainly in rural areas where rice crops are cultivated and
where the Culexmosquito favours sources of stagnant water in which to breed. Most people liv-
ing in rural Asia are infected during childhood, but few of those infected become symptomatic.
Those that do develop symptoms, usually present with severe meningo-encephalitis and sei-
zures [3]. Around 20–30% of patients with neuroinvasive JEV infection die, and half of the sur-
vivors have severe neurological sequelae. This imposes a huge socioeconomic burden in the
poor rural settings where JEV is found [4].
Although vaccines against JEV have become more widely used in recent years, the animal
reservoir cannot be eradicated, so JEV remains a threat. The virus has continued to spread and
at present there is no established treatment for JEV, or other related flaviviruses such as WNV.
The pathogenesis of Japanese encephalitis (JE) is believed to involve a combination of viral
cytopathology and immunopathology [5–8]; previous attempts to develop treatment have ex-
plored both of these. After entering the body through the bite of an infected mosquito, JEV am-
plifies in the dermal tissues and lymph nodes leading to viremia. Virions are thought to then
bind to the vascular endothelial surface within the CNS, be internalized by endocytosis and
transferred across the endothelial cells [2]. In the brain, JE is characterized as perivascular in-
flammation with recruitment of macrophages, neutrophils and lymphocytes [9–11]. The thala-
mus, basal ganglia, midbrain and anterior horns cells of the spinal cord are particularly affected
[12, 13]. Viral antigen is predominantly in neurons although microglial cells, astrocytes and
vascular endothelial cells are also infected. JEV is thought to cause neuronal cell death in two
ways; firstly, direct neuronal killing [14, 15], whereby viral multiplication within neuronal cells
leads to cell death; secondly, indirect killing, whereby the over activation of microglia, astro-
cytes and recruited macrophages [16] leads to release of excess proinflammatory cytokines
such as interleukin 6 (IL-6), TNF-α, and RANTES (regulated upon activation, normal T cell
expressed and secreted), which are thought to damage neuronal cells, and increase the
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permeability of the blood brain barrier and promoting massive leukocyte migration into the
brain and further neuronal cell death [17].
The role of corticosteroids in the treatment of JE was examined in a randomized-placebo
controlled trial in Thailand; although dexamethasone caused a reduction in cerebrospinal
(CSF) opening pressures and CSF white cell counts, there was no overall benefit in terms of
outcome [18]. Interferon-α (IFN-α) is produced as part of the innate response to JEV infection,
and has antiviral activity against JEV; but a placebo-controlled trial in Vietnam found it did
not improve outcome [19]. Oral ribavirin also proved to be unhelpful in a controlled trial in
India [20]. Intravenous immunoglobulin (IVIG) has been postulated as a potential treatment
for flavivirus encephalitis caused by JEV andWNV, on account of its antiviral and anti-inflam-
matory properties. It has been used on a compassionate basis, but has not been assessed in a
randomized trial for either virus [17, 21]. IVIG is postulated to act in two ways; IVIG produced
in countries where flaviviruses are endemic contains high titers of specific neutralizing anti-
body, because most of the population have been exposed to the virus, and thus have antibodies
[22]. In addition IVIG has non-specific anti-inflammatory properties, particularly through the
suppression of pro-inflammatory cytokines. However IVIG is more difficult to administer than
intravenous IFN-α, intravenous corticosteroids or oral ribavirin [23, 24]; it is delivered using a
syringe driver, and must be started at a low infusion rate, being increased over time if it is well
tolerated. Where-as the previous trial using intravenous agents were conducted in settings with
highly developed research infrastructure in Thailand and Vietnam, Nepal has no such estab-
lishments. We therefore conducted a preliminary randomized placebo-controlled trial of IVIG
treatment in children with suspected JE in Nepal, primarily to assess feasibility. We also used
the opportunity to begin examining changes in immune parameters associated with such
treatment.
Methods
Ethics Statement
The study protocol was approved by the Nepal Health Research Council, and the ethics com-
mittees of BPKIHS, Kanti Children’s Hospital and the Liverpool School of Tropical Medicine.
Informed written consent was obtained for all children from parent or legal guardian. Written
consent was also obtained from JEV vaccinated individual.
IVIG selection
JEV-specific neutralizing antibody titre was measured in pharmaceutical grade IVIG obtained
from four different suppliers from areas endemic for JEV [Bharat serum, India; Hualan Biolog-
ical Engineering Inc., China; Sichuan Yuanda Shuyang Pharmaceutical Co., China; Reliance
Biopharmaceutical, India] by 50% plaque reduction neutralization titres (PRNT50) against wild
type JEV (strain P3) infecting a standard culture of Vero cells. IVIG from a low JEV prevalence
region (Vigam, Bio Products Laboratory, USA) and a sample of serum from a JEV vaccinated
individual were tested as controls. The test was repeated three times. IVIG produced by Reli-
ance Biopharmaceuticals Pvt. Ltd. in India and manufactured in China from blood donors in
an endemic area known to have high levels of JEV seroprevalence had the highest mean JEV
PRNT50, titre and was selected for use in this trial. In order to confirm the JEV-specific neutral-
izing antibody titre as well as characterise background immunity to other flaviviruses known to
circulate in Asia, the IVIG was tested by dengue virus (DENV), tick-borne encephalitis virus
(using Powassan virus), and WNV IgM and IgG antibody capture ELISA and PRNT90 at the
US Centers for Disease Control and Prevention (CDC) Division of Vector-Borne Diseases
[25–28]. The lower limit of quantitation (LLOQ) by PRNT90 was 1:10 serum dilution.
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Patients
Patients were recruited from two centers in Nepal: Kanti Children’s Hospital in Kathmandu,
which is the main pediatric center in Nepal, and the Paediatric Department at BP Koirala Insti-
tute of Health Sciences (BPKIHS), a large regional hospital in the town of Dharan in the eastern
lowland Terai area of Nepal. The JEV mosquito vector is uncommon in Kathmandu due to the
elevation of 1350 meters (4400 feet) and most cases at Kanti Children’s Hospital were referred
to this center from the central lowland Terai area where the disease is endemic.
During the monsoon period fromMay to June 2009 we recruited children aged between 1
and 14 years who had clinically diagnosed acute encephalitis syndrome (AES). On the basis of
results from previous studies [19, 29] AES was diagnosed clinically in children who had a histo-
ry of fever that lasted less than 14 days, altered consciousness [Glasgow coma score (GCS)
<15] with or without a history of seizures, and consistent cerebrospinal fluid (CSF) findings.
The CSF criteria for a clinical diagnosis of encephalitis were a white cell count less than 1000
cells/mm3 with no organisms on Gram stain and a CSF:plasma glucose ratio> 40% [3]. Chil-
dren with a single seizure lasting less than 15 minutes with full recovery of consciousness with-
in 60 minutes were assumed to have had a febrile convulsion and excluded. We also excluded
those with a positive blood slide or rapid antigen test for Plasmodium falciparum parasites and
those referred from a peripheral health center who had clinical and/or laboratory features sug-
gestive of bacterial meningitis where antibiotic treatment had already been commenced. Chil-
dren with a GCS< 3 (out of 15), who were receiving artificial ventilation without signs of
spontaneous respiration, and with absent oculocephalic reflex were excluded, as prior studies
have shown an extremely low chance of meaningful recovery [3, 30].
Procedures
We randomly allocated patients to treatment with IVIG or placebo. Randomization was strati-
fied by each centre using a variable block size of 4, 6 or 8, selected on a random basis similar to
those schemes used previously [10]. The randomization code for each patient was kept in a
sealed envelope in a locked cupboard on a separate ward (Randomization schedule is provided
as S1 Table). Once a patient was enrolled, technicians who were not otherwise connected to the
study opened the envelope, drew up the study drug, covered the syringe in opaque tape (be-
cause of subtle differences in colour and viscosity of the two substances) and delivered it to the
ward, where the nurses gave the treatment. Children received either saline or intravenous im-
munoglobulin (IVIG) [ImmunoRel (batch 20081217)] at a dose of 400mg/kg/day for 5 days or
an equivalent volume of 0.9% normal saline. The infusion was started at an initial rate of 0.01
to 0.02 ml/kg body weight/minute and if well tolerated the rate was gradually increased over 30
to 60 minutes to a maximum rate of 0.08 ml/kg body weight/minute. Empty vials were con-
cealed in paper bags and disposed of. Hence, all investigators, care providers and participants
were blinded of the study drug. A second sealed envelope was kept at the back of each patient’s
inpatient notes in case a physician urgently needed to know which drug a patient had received.
We took a detailed history and a member of the study team did daily clinical and neurological
examinations (or more frequently if needed) until death or discharge. The primary aim was to
assess the feasibility of a multicentre placebo-controlled RCT of IVIG in this resource-poor set-
ting. Secondary outcomes were death or neurological sequelae at discharge or follow up and,
adverse events. In particular side effects monitored were infusion site reaction, diarrhoea, rise
in blood pressure and change in urinary output daily from first day of commencing treatment
which was on first day of hospital admission until death or discharge which was on average on
eighth day. We also wanted to examine any difference in anti-JEV antibody titres between chil-
dren treated and untreated with IVIG. Adverse events were graded using WHO
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recommendations and reported to an independent data safety monitoring committee. Infor-
mation was recorded on standardized proformas. Computer tomography scans were per-
formed as indicated at the discretion of the admitting physician. There were no onsite facilities
for magnetic resonance imaging. Patients with prolonged or repeated seizures, respiratory diffi-
culties or severely reduced consciousness, were admitted to a paediatric intensive care unit,
which had facilities to intubate and ventilate. Mannitol and dexamethasone were given at the
discretion of the admitting physician, and suspected septicaemia was treated with broad-spec-
trum antibiotics. Patients were assessed at discharge and 3–6 month follow-up for disability in
a range of activities using the Liverpool Outcome Score [31] and a standardized neurological
assessment. The Liverpool Outcome Score assesses speech, communication, feeding, ability to
be left alone, behaviour, recognition, school or working, seizures, dressing, bladder/bowel con-
trol, hearing, sitting, standing, walking and upper limb dexterity. Children were classified as I if
the child died; II, if there were severe sequelae causing impairment of function likely to make
the child dependent on others; III, if there were moderate sequelae only mildly affecting func-
tion, probably compatible with independent living, IV, if there were minor sequelae with mild
effects on function or personality change or on medication; V, if there was complete recovery
which included normal examination (http://www.liv.ac.uk/infection-and-global-health/
research/brain-infections-group/education.). Children who did not return for follow-up were
reminded by letter or telephone, as available. If they were unable to return to the hospital, they
were examined at home. At follow-up, we took particular note of seizures, progress at school,
and changes in personality. The trial protocol is available as S1 Protocol and online (http://
clinicaltrials.gov/show/NCT01856205). CONSORT checklist is provided as S1 Checklist
CONSORT.
Diagnostic and Pathogenesis studies
On admission patients had routine blood tests (typically; a full blood count and white cell dif-
ferential, glucose, urea and electrolytes) and a blood film or rapid antigen test for Plasmodium
falciparum. For diagnostic and pathogenesis studies, we took blood prior to treatment (IVIG or
placebo) and 1 hour after the completion of infusion of the 5th (final) dose. If a child required
further blood tests for clinical reasons, extra samples were collected. Serum was separated by
centrifuge, frozen at -20°C; aliquots were made and one aliquot went to the designated labora-
tory in Nepal for testing; the other aliquots were transported on dry ice to the Institute of Infec-
tion and Global Health, Liverpool, UK, and subsequently to CDC Division of Vector-Borne
Diseases in Fort Collins, Colorado, USA.
On admission, we did a lumbar puncture with patients in the lateral position, and if the pa-
tient was calm the opening pressure was recorded using a cerebrospinal-fluid manometer. The
lumbar puncture was delayed in patients who were convulsing, or those with clinical signs of
raised intracranial pressure [32]. CSF samples were examined for cell count and differential,
protein, glucose and Gram stain. Further CSF and serum samples were frozen on site at -20°C,
and subsequently transported for further investigations, as above.
To diagnose JE locally, anti-JEV immunoglobulin-M (IgM) antibodies were measured in all
serum samples on admission and day 7 of admission, and in all CSF samples by enzyme-linked
immunosorbent assay (ELISA) using the AFRIMS JE MAC IgM ELISA as part of the WHO
acute encephalitis syndrome surveillance programme; these samples were measured in batches
at the National Public Health Laboratories in Kathmandu, and so the results were not available
at the time of randomisation. Classification of the patients as JE negative or positive was based
on the results of this initial JEV IgM ELISA testing in Nepal, confirmed at CDC, USA, as
below.
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Confirmatory testing was subsequently performed at the CDC Arboviral Diseases Branch
diagnostic laboratory using the following testing algorithm. The last serum sample collected
from each patient was tested by JEV and DENV IgM capture ELISA. Positive or equivocal re-
sults were confirmed by JEV and DENV PRNT90, with a 4-fold or greater difference in titre in-
terpreted to be virus specific. If the last sample was positive or equivocal for JEV and/or DENV
IgM, all samples for that case were tested. However, if the last serum sample from a patient was
collected at less than 7 days post onset of disease and had an IgM ELISA negative result, the
CSF from that patient was also tested by JEV and DENV IgM ELISA.
In addition, if the last serum sample collected from a case had a negative JEV and DENV
IgM ELISA result and was collected<10 days from illness onset, CSF was tested for the presence
of JEV ribonucleic acid (RNA) by two real-time reverse transcription-polymerase chain reaction
(RT-PCR) assays, one designed in-house at CDC (JEV239F: GGCTCTTATCACGTTCTTCAA
GTTT; JEV344R: ACTAGTAAGATGTTTCATTGCCACACTCT; JEV269probe: ATTA
GCCCCGACCAAGGCGCTTT) and other developed by Parida et al. [33]. Both assays had
sensitivities of 0.001 equivalent plaque forming units for SA-14-14-2 reference viral RNA [33].
Viral RNA was extracted from 100μl of CSF, eluted in 50 μl using the QIAamp Viral RNAMini
Kit (QIAGEN, Valencia, CA); 20 μl RNA template was used in a 50μl reaction using the iScript
One-Step RT-PCR kit for Probes (BioRad, CA).
To study in more detail the effect of IVIG on the neutralising antibody titres, JEV PRNT50
was done on serum from all patients at pre-treatment (immediately prior to the first dose), and
post-treatment (1hour after the 5th dose).
Interleukin (IL) -6 and IL-4 cytokine measurements were undertaken on aliquots of IVIG
and on patients’ serum pre-treatment (before first dose) and post-treatment (1 hour after 5th
dose), using ELISA kits following the manufacture’s protocol (Bender MedSystems GmBh,
Wien, Austria). Samples were measured in duplicate (50ul) at each time-point. Quality control
was based on concurrent measurement of negative and positive controls supplied in the kits.
Sample size
The primary aim of this study was to examine feasibility, through studying approximately 20
patients across two sites. In addition, we wished to determine if there were any adverse effects
of IVIG or any differences in presence of anti-JEV antibody titres following administration of
IVIG and placebo. To our knowledge, there are no previous human clinical trials of IVIG
among JE patients to guide sample size. Similarly, they have been no toxicity studies of IVIG in
animals with JE. However, there are data on change anti-JEV titre associated with improved
outcome in mice given immune splenocytes. In the latter study, mice given immune spleno-
cytes generated a mean anti-JEV titre of 400, whereas mice given naïve splenocytes exhibited a
mean anti-JEV titre of 40. Based on these data, using a significance of 0.95 and a power of 0.8,
mean titres of 400 and 40 and a standard deviation of 400 and 40 for anti-JEV antibody titres
in IVIG exposed and non-exposed respectively, we required 10 subjects in each arm. To allow
for loss to follow up of 10–20% we aimed to recruit 22–24 patients. This small sample size
would also allow us to look for any adverse events associated with treatment, accepting that for
a true dose-limiting toxicity of 0.05 and 11 JEV subjects receiving IVIG, the probability of ob-
serving at least one dose-limiting toxicity associated with IVIG was only 0.4312.
Statistical analysis
Patient clinical features and laboratory parameters were compared between treatment groups
(IVIG or placebo). Difference in plaque reduction anti-JEV antibody neutralizing titres
(PRNTs) pre and post treatment were also compared between treatment groups (IVIG or
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placebo). Similarly, the difference in cytokine abundance pre and post treatment (separately
for IL4 and IL6) were compared between treatment groups. Normally distributed data were
compared using Student’s t-test. Non-normally distributed data were compared using the Wil-
coxon-Mann-Whitney test. Differences between proportions were tested using the Fisher’s
exact test. To examine whether JE antibody status of the participant prior to treatment was a
source of variation in difference in antibody titres or cytokine abundances following treatment,
a 2 way ANOVA was undertaken, where treatment (IVIG or placebo) was the column factor
and JE status (anti-JEV antibody positive or negative) was the row factor. Prism ver.6.04
(Graph Pad Software, Inc) was used for statistical analyses and graph generation.
Results
Patients
Between May and September 2009, 22 (96%) children of 23 screened met the entry criteria; 12
in Kanti Children’s Hospital in Kathmandu and 10 in BPKIHS in Dharan. One child was not
enrolled in the trial as he was moribund and met criteria for exclusion. Eleven (50%) received
IVIG and 11 (50%) placebo (Fig 1). Twenty-two patients were randomized and there were no
breaches of randomization protocol. None of the children were reported to have been vaccinat-
ed against JE. Seven (64%) patients in the IVIG group and 6 (55%) in the placebo group were
classified as acute JEV infections by JEV/DENV IgM ELISA testing. The initial JE diagnostic
classification for all patients in Nepal was confirmed by the testing at the CDC, USA. Seven out
of 10 (70%) were positive for JEV in BPKIHS and 6 of 12 (50%) in Kanti Children’s Hospital.
One child (placebo group) had evidence of a previous flavivirus infection. One patient with an
undetermined status after local testing was found to be JEV negative by confirmatory testing at
CDC; otherwise there was complete concordance between the test results in Nepal and those at
CDC. All CSF tested were negative for JEV RNA by real time RT-PCR.
The baseline characteristics of the two groups were comparable (Table 1). The median age
was 5 and 7 years for treatment and placebo groups respectively (not significantly different).
Most patients came from rural areas, and arrived after approximately 5 days of illness. Median
GCS on admission was 8 (range 5–15), and the majority of patents had seizures as part of the
presenting syndrome. All concurrently received antibiotics, most commonly cephalosporins.
Four patients received dexamethasone alongside study drug; all 4 were in the placebo arm. One
child received only 1 dose, 2 children had 2 doses each, and 1 child had daily dexamethasone
for 5 days (Raw data of patients’ characteristics is available as S2 Table).
The adverse and serious adverse events, according to patients’ JEV status, and whether they
received IVIG or placebo is presented in Table 2; there were no significant differences in fre-
quency of adverse events between IVIG and placebo. There were no suspected unexpected seri-
ous adverse reactions (SUSARs). Raw adverse events data is available in S3 Table.
Intravenous immunoglobulin
All IVIG preparations produced in JEV endemic regions had anti-JEV PRNT50 titres, ranging
from 1:320 to 1:640 (Fig 2). Control IVIG from a non-JEV endemic area (Vigam, USA) showed
minimal PRNT50 titres of 1:10; lower than serum from a JEV vaccinated individual who had a
titre of 1:40. ImmunoRel IVIG produced by Reliance Biopharmaceutical (India) had the high-
est anti-JEV PRNT50 titre, and was chosen for treatment in this study. This ImmunoRel IVIG
showed low PRNT50 titres1:20 against DENV, WNV and Powassan viruses.
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Outcomes
One patient, who received the study drug, died of aspiration pneumonia. He was a 19 month
old boy admitted with a 13 day history of high grade fever, repeated generalized tonic clonic
seizure, fast breathing and altered sensorium. He had not been immunized against JE. His Glas-
gow Coma Score 10/15, pulse 140 per minute, respiratory rate 56 breaths per minute, axillary
temperature 38.9°C, and he had diffuse wheeze in both the lung fields. On neurological exami-
nation he had a right sided hemiplegia. Investigations revealed a peripheral blood total white
cell count of 25.4x109 cells/L (polymorphs 66%, lymphocytes 31%), serum creatinine 0.6 mg/
dl, serum sodium 143 mmol/L, serum potassium 4.5 mmol/L. His CSF was clear and colourless
with 10 cells/mm3 (polymorphs 40%, lymphocytes 66%), protein 80mg/dl, glucose 48mg/dl
(blood glucose 87 mg/dl). He was treated with intravenous ceftrioxone 100mg/kg/day for two
days, intravenous midazolam at 0.2mg/kg/dose for two doses, intravenous phenytoin at 20mg/
kg loading dose, followed by 7 mg/kg/day of maintenance dose, intravenous 20% mannitol at
5ml/kg single dose and maintenance intravenous fluids, but died on the fourteenth day of ill-
ness. Un-blinding after death revealed he had received IVIG (2 grams per kilogram body
weight) at 0.01mL/Kg/minute on the first and second day. He was subsequently found to be
JEV IgM negative. The investigating member of the Data Safety & Monitoring Committee
Fig 1. Flow diagram of study participants’ recruitment and follow-up. All children enrolled, fitting the trial
criteria, who were alive at discharge were attempted to be followed-up (n = 21). Twenty-one families were
successfully contacted. Among these families, two children had died.
doi:10.1371/journal.pone.0122608.g001
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confirmed that the child died of aspiration pneumonia due to repeated uncontrolled seizures,
unrelated to the study drug.
The remaining 21 patients received the full 5 days of treatment. At hospital discharge, the
commonest Liverpool outcome score was II (major sequelae) in both IVIG and the placebo
Table 1. Baseline characteristics of trial participants.
Parameters No. IVIG (n = 11) No. Placebo (n = 11) P
Age (years) 11 5 (1–11) 11 7 (1.3–12) NS.
Male 11 5 (.45) 11 7 (.64) NS.
Living in rural area 11 11 (1) 11 9 (.82) NS.
Fever duration (days) 9 5 (2–12) 11 5 (3–10) NS.
Illness duration (days) 10 5 (4–13) 11 6 (3–13) NS.
Altered sensorium 11 10 (.91) 11 9 (.81) NS.
New onset seizures 11 10 (.91) 11 11 (1) NS.
Glasgow Coma Scale (3–15) on admission 11 8 (5–15) 11 8 (5–15) NS.
Temperature (°C) 10 38.3 (36.7–40) 10 38.9 (36.7–40) NS.
Heart rate (beats/minute) 10 95 (68–140) 11 104 (84–130) NS.
Resp. rate (breaths/minute) 10 33.5 (22–56) 11 28 (22–40) NS.
Neck stiffness present 11 4 (.36) 11 4 (.36) NS.
Kernig's sign present 11 1 (.09) 10 2 (.18) NS.
Abnormal limb tone 8 5 (.63) 9 3 (.3) NS.
Abnormal posturing 9 2 (.22) 11 0 (0) NS.
Positive anti-JEV IgM 11 7 (.64) 11 6 (.55) NS.
Haemoglobin (g/dl) 9 12.1 (9.8–13.8) 10 11.8 (8.2–14.3) NS.
White cell count (WCC)—x109/L 9 10.8 (5.2–25.4) 11 13.9 (4.2–18.9) NS.
Polymorphs (%) 9 66 (30–85) 11 68 (30–90) NS.
Lymphocytes (%) 9 31 (12–70) 11 30 (10–70) NS.
Platelets (x109/L) 7 270 (120–659) 9 200 (88–362) NS.
Glucose (mg/dl) 11 100 (80–160) 11 85 (66–170) 0.03
Urea (mg/dl) 7 22.8 (15–35) 9 27.0 (18–58) NS.
Creatinine (mg/dl) 7 0.9 (0.4–2.4) 9 1 (0.5–2.2) NS.
Cerebrospinal ﬂuid (CSF) WCC-cells/mm3 11 35 (0–125) 11 30 (0–300) NS.
CSF polymorphs (%) 11 10 (0–60) 11 10 (0–95) NS.
CSF lymphocytes (%) 11 70 (0–100) 11 40 (0–100) NS.
CSF protein (mg/dl) 11 39 (28–100) 10 27 (7–68) 0.01
CSF glucose (mg/dl) 11 70 (48–90) 10 61.5 (45–81) NS.
CSF/blood glucose ratio 11 62 (50–82) 10 68.5 (46–100) NS.
Mannitol (given) 11 3 (.27) 11 7 (.64) NS.
Dexamethasone 9 0 (0) 11 4 (.36) NS.
Quinine 11 5 (.45) 11 5 (.45) NS.
Aciclovir 11 1 (.91) 11 2 (.18) NS.
Chloramphenicol 11 1 (.91) 11 0 (0) NS.
Cephalosporin 11 10 (.91) 11 10 (.91) NS.
Phenytoin 11 9 (.82) 11 8 (.73) NS.
Phenobarbitone 11 3 (.27) 11 2 (.18) NS.
Data presented as number of patients (proportion) or median (range). No.—number of patients in the clinical group where data for the parameter was
available. P—P value for Fisher’s Exact or Mann Whitney U test between groups.
NS.—not signiﬁcant.
doi:10.1371/journal.pone.0122608.t001
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groups [7/11 (64%) and 8/11 (73%) patients per group respectively]. When all participants are
included at 3–6 month follow-up; 6 out of 11 (45%) exhibited complete recovery (no neurolog-
ical sequelae) in the IVIG group compared to 2 out of 11 (18%) in the placebo group (Table 3).
There was no significant difference in the proportion of patients exhibiting complete recovery
between the two groups when analyzed by intention-to-treat either at hospital discharge or at
follow-up [p = 1 and 0.36 respectively (Table 3)].
Neutralizing antibodies
The difference in neutralizing antibody titres pre and post treatment were analysed by treat-
ment group (IVIG or placebo) Neutralizing antibody titres increased significantly among
Table 2. Summary of adverse events.
Symptoms IVIG Placebo IVIG vs.
Placebo
IVIG vs.
Placebo
JE
(n = 7)
Non-JE
(n = 4)
Total
(n = 11)
JE
(n = 6)
Non-JE
(n = 5)
Total
(n = 11)
P- value OR(95% CI)
Fever 2 (.29) 2 (0.5) 4 (.36) 1 (.17) 1 (0.2) 2 (.18) 0.64 2.6 (0.3–29)
Dyspnoea 1(.14) 2 (0.5) 3 (.27) 1 (.17) 1 (0.2) 2 (.18) 1 1.7 (0.2–20.1)
Vomiting 0 (0) 0 (0) 0 (0) 1 (.17) 0 (0) 1 (0.9) 1 0 (0–18.7)
Irritable 1(.14) 1 (.25) 2 (.18) 2 (.33) 0 (0) 2 (.18) 1 1 (0.07–13.5)
Non-urticarial skin
rash
0 (0) 0 (0) 0 (0) 1 (.17) 0 (0) 1 (0.9) 1 0 (0–18.7)
Hypotension* 1(.14) 0 (0) 1 (0.9) 1 (.17) 0 (0) 1 (0.9) 1 1 (0–43.7)
Melena* 1(.14) 0 (0) 1 (0.9) 0 (0) 1 (0.2) 1 (0.9) 1 1 (0–43.7)
Death* 0 (0) 1(.14) 1 (0.9) 0 (0) 0 (0) 0 (0) 1 NA
Data are number of patients (proportion).
* Serious adverse events. NA: not applicable
doi:10.1371/journal.pone.0122608.t002
Fig 2. Anti-JEV neutralizing antibody in commercially available IVIG.Mean and standard deviation of
reciprocal 50% plaque reduction neutralization titres (PRNT50) in vero cells using P3 wild type strain of JEV
are shown for a: Serum control from JEV vaccinated individual, b: Vigam (USA), c: Bharat (India) batch 1, d:
Hualan (China) batch 1, e: Bharat (India) batch 2, f: Hualan (China) batch 2, g: Sichuan (China), h: Reliance
(India).
doi:10.1371/journal.pone.0122608.g002
IVIG Treatment of JE in Nepal
PLOS ONE | DOI:10.1371/journal.pone.0122608 April 17, 2015 10 / 21
participants who received IVIG compared to placebo (p = 0.038: Fig 3). Separating results by
anti-JEV IgM antibody status, titres showed a greater increase among those who received IVIG
compared to placebo in both anti-JEV antibody status groups. The median increase in neutral-
izing antibody titre was greater (16 fold) in anti-JEV IgM positive compared to negative pa-
tients (median increase in titre post treatment was 1920 versus 120 for IgM positive and
Table 3. Outcome for trial participants.
Outcome at discharge IVIG (n = 11) Placebo (n = 11) P-value OR (95% CI)
Median duration of hospital stay (days) 13 (9–21) 12 (6–18) 0.59 -
Median Glasgow coma score 14 (3–15) 14 (7–15) 0.53 -
Number with complete recovery (LOS V) 1 (.09) 1 (.09) 1 1 (0–43.7)
Number with minor sequelae (LOS IV) 0 1 (.09) 1 0 (0–18.7)
Number with moderate sequelae (LOS III) 2 (.18) 1 (.09) 1 2.2(0.1–74.9)
Number with severe sequelae (LOS II) 7 (.64) 8 (.73) 1 0.7 (0.07–5.5)
Number that died (LOS I) 1 (.09) 0 1 NC
Outcome at 3–6 months IVIG (n = 11) Placebo (n = 11) P-value OR (95% CI)
Lost to follow-up 2 (.18) 2 (.18) 1 1 (0.07–13.5)
Number with complete recovery (LOS V) 5(.45) 2 (.18) 0.36 3.8 (0.4–41.8)
Number with minor sequelae (LOS IV) 0 3 (.27) 0.21 0 (0–2.2)
Number with moderate sequelae (LOS III) 1 (.09) 0 (0) 1 NC
Number with severe sequelae (LOS II) 2 (.18) 2 (.18) 1 1 (0.07–13.5)
Number that died (LOS I) 1 (.09) 2 (.18) 1 0.45 (0.01–8.4)
Data are number of patients (proportion) or median (range). LOS = Liverpool Outcome Score (LOS): 1—died; 2—severe sequelae; 3—moderate
sequelae; 4—minor sequelae; 5—full recovery. NC: not calculable
doi:10.1371/journal.pone.0122608.t003
Fig 3. Difference in neutralizing antibody titres to JEV in children with acute encephalitis syndrome
treated with IVIG or placebo.Median and inter-quartile range of the difference in JEV PRNT50 titres pre and
post treatment is presented. Patients are grouped according to treatment. Difference in tires was assessed
via Wilcoxon-Mann-Whitney test. Note: Two patients who received IVIG were not included in this analysis
because of insufficient sample to undertake PRNTmeasurements.
doi:10.1371/journal.pone.0122608.g003
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negative patients respectively; S4 Table and S1 Fig). However, the increase in neutralizing anti-
body titres following IVIG treatment was only significant among anti-JEV IgM negative pa-
tients (p = 0.048 and p = 0.24 respectively). Patient anti-JEV IgM status prior to treatment was
not a significant source of variation in change in neutralizing antibody titre as assessed by 2
way ANOVA (p = 0.29; S5 Table).
Cytokines
The difference in cytokine abundance pre and post treatment were also analysed by treatment
group (Fig 4). Cytokine abundance for both IL-6 and IL-4 increased among participants who
received IVIG compared to placebo. This increase was significant for IL-4 (p = 0.043). Separat-
ing the IL-4 results by anti-JEV IgM antibody status, IL-4 levels showed a greater increase
among those who received IVIG compared to placebo in both anti-JEV antibody status groups.
The median increase in IL-4 following IVIG treatment was greater (13 fold) in anti-JEV IgM
negative compared to positive patients (median increase in abundance post treatment was 0.65
versus 0.05 pg/ml for IgM negative and positive patients respectively). Neither increase was sig-
nificant; p = 0.06 and p = 0.6 for IgM negative and positive patients respectively (S6 Table; S7
Table; S2 Fig). Patient anti-JEV IgM status prior to treatment was a significant source of varia-
tion in change in IL-4 abundance (p = 0.0018). However, treatment (IVIG or Placebo) was a
more significant source of variation as assessed by 2 way ANOVA (p = 0.0005). Patient anti-
JEV IgM status prior to treatment was not a significant source of variation in change for IL-6
(S5 Table). A very low concentration of IL-6 was detected in the IVIG (0.4 pg/ml). IL-4 was not
detected. Raw data for PRNT levels are available in S8 Table.
Discussion
JEV, the most important cause of epidemic encephalitis globally, is just one of several impor-
tant flaviviruses that cause encephalitis. These include tick-borne encephalitis virus, which oc-
curs across northern and eastern Europe, and WNV, which circulates in India, Africa, Europe,
and since 1999, the Americas. There is no established treatment for any flavivirus. Although JE
vaccine programs are being implemented across Asia, the disease is continuing to spread, and
recent estimates put the incidence closer to 70,000 cases annually, rather than the previously
estimated 50,000. [34]. JE was first recorded in Nepal in 1978 in Rupandehi district of the
Western Development Region [35]. It is currently endemic in 24 districts with sporadic reports
from a further 33 of the total 75 districts. Up to 2012 there were 29,877 clinically diagnosed
cases with 5,589 deaths (personal communication: Dr Santosh Gurung, Programme for Immu-
nization Preventable Diseases, WHO, Kathmandu, Nepal) In the early outbreaks, the mortality
was up to 60%, but more recently this has improved to approximately 20% [30, 35]. Immuniza-
tion against JE began in 1999 in 3 districts [36, 37], which had been extended to cover 31 high
risk districts by 2011. In addition, the Government vaccinated around 200 000 pigs in the Terai
zone in 2001 [35]. A recent seroprevalence study in animal hosts in 10 districts in Nepal re-
vealed that 48% of pigs, 27% of ducks and 50% of horses were JEV seropositive demonstrating
a high transmission of JEV in the wild and confirming that it is likely to remain [38]. Hence, JE
is still a major public health problem in Nepal, and there is a pressing need to develop better
treatments.
Our pilot study suggests that a multi-centre RCT of IVIG for children with suspected JE is
feasible in this setting with no protocol violations. The double-blinding procedure, using mask-
ing tape to cover syringe contents, has been used in a previous study of IFN-α in JE in a very
well resourced research unit in Vietnam, which employs research nurses and technicians [23];
we found that it also worked well in this much simpler setting with hospital nurses and
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technicians. In considering the study, there had been concern that starting an infusion at a low
rate, and then increasing over time would be unacceptable to hospital staff if they could not see
what drug they were giving; but again this aspect worked well. Although our numbers were
small, we did not detect any significant differences in adverse events between the two groups.
We did not study the minimum 30 subjects recommended by US FDA Guideline on Safety, Ef-
ficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous
(Human) as Replacement Therapy for Primary Humoral Immunodeficiency (2008)(http://
www.gmp-compliance.org/guidemgr/files/IGIVIMMUNO.PDF). Nor did we employ a dose
escalation designs used in many oncology studies. However we were not studying Primary Hu-
moral Immunodeficiency or cancer, and recommendations from western settings may not al-
ways be appropriate for studies in resource-poor settings [39]. Three patients died. The one
death in the IVIG group was attributed to severe underlying disease rather than the IVIG, and
the two deaths which had occurred by follow-up were both in the placebo group. The propor-
tion of patients exhibiting full recovery (without any sequelae) was similar between the groups
at discharge and slightly higher among in the IVIG group at follow. This difference was not sig-
nificant on intention-to-treat analysis.
In Nepal, IVIG, which has general anti-inflammatory effects, is currently being used to treat
a range of pediatric conditions including Guillain-Barré syndrome, idiopathic thrombocytope-
nic purpura and Kawasaki disease. IVIG from endemic areas is considered a potential
Fig 4. Interleukin (IL)-4 and IL-6 abundance in children with acute encephalitis syndrome receiving
intravenous immunoglobulin (IVIG) and placebo.Median and inter-quartile range of change in cytokine
abundance (pg/ml) pre and post treatment is presented for IL-4 and IL-6 separately. Cytokine abundance
increased for both IL-4 and IL-6. This increase was significant for IL-4 (p = 0.043 and p = 0.068 for IL-4 and IL-
6 respectively). Difference in abundance was assessed via Wilcoxon-Mann-Whitney test. Note: Four patients
(three who received IVIG and one who received saline) were not included in this analysis because of
insufficient sample to undertake the ELISA.
doi:10.1371/journal.pone.0122608.g004
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treatment for flavivirus encephalitis, including that caused by JEV and WNV, because of the
neutralizing antibody it contains [24]. We found IVIG from a range of manufactures in Asia
contained significant neutralizing antibody; most had PRNT50 titres1:640. Pre-clinical stud-
ies suggest that passively transferred antibody may be effective against flavivirus encephalitis
[17, 21, 24, 40–46]. Konishi et al demonstrated that neutralizing antibody prevents virus dis-
semination from the peripheral site to the brain, and that antibody-mediated mechanisms of
protection were more efficient than cytotoxic T cell responses [43]. In animal studies in which
IVIG containing anti-WNV specific antibody was administered during the viraemic phase but
before the virus had entered the CNS, there was a dramatic 100% survival rate [24, 44], and
mortality was reduced up to five days after infection [45, 46]. More relevant for the treatment
of patients presenting to hospital with WN neuroinvasive disease, in which the virus has al-
ready entered the CNS, Morrey et al showed that peripheral administration of anti-virus
monoclonal antibodies in a mouse model neutralizes WNV even after it has entered the brain
[47, 48].
As expected, patients had a greater increase in neutralizing antibody titres among those
treated with IVIG compared to placebo. Interestingly JEV antibody positive children treated
with IVIG exhibited higher (approximately 16 times higher) titres of neutralizing antibody
compared to levels of change following IVIG treatment among JEV antibody negative patients
(this change was not significant). The magnitude of this effect appears greater than can be ex-
plained by passive transfer of anti-JEV antibody (observed as the increase titres among the JE
negative patients). The reason for this is not certain, though it is possible that passively trans-
ferred antibody is enhancing the natural production of neutralizing antibody by B cells, per-
haps through augmenting the uptake of viral particles by antigen presenting cells. Such a
mechanism has been described in a macaque model of HIV, where the administration of low
level neutralizing monoclonal antibodies to simian HIV led to the rapid development of neu-
tralizing antibodies through enhanced B cell responses [49]. A relatively modest neutralizing
antibody titre (i.e. 1:10) has been shown to protect against JEV in animal models, when anti-
body is administered prior to infection. However, to our knowledge, no studies have deter-
mined what titre is required to limit the evolution of encephalitis once JEV infection is
established in humans. Our patients all had an antibody titre that was much higher, around
100 fold higher, than this and yet still had encephalitis.
Antibody-dependent enhancement of viral entry into macrophages is also important in sec-
ondary DENV infections. In this case non-neutralising antibody from a prior infection with a
different DENV serotype is thought to enhance viral entry into macrophages and contribute to
increased disease severity [50]. In tick-borne encephalitis, passive immunization with neutral-
izing antibody containing IVIG has been used as prophylaxis in those bitten by infected ticks,
before disease develops [51]. However, following suspicions that this was actually precipitating
disease, through postulated antibody dependent enhancement, this approach was abandoned.
Our study suggests there were no significant side effects of treatment with IVIG in JE and ad-
ministration was associated with increased JEV-specific serum neutralizing antibody titres.
Neuronal cell death in JE may occur directly, from viral cytopathology, and indirectly via
immune mediated mechanisms.This may include over activation of microglia cells [52], which
release pro-inflammatory cytokines such as interleukin 6 (IL-6), TNF-α, and RANTES (regu-
lated upon activation, normal T cell expressed and secreted), causing massive migration and
infiltration of leukocytes into the brain [53]. IL-6, which is produced by neurons, microglia, as-
trocytes and recruited macrophages in response to viral CNS infection [54–56], causes an in-
creased permeability of the blood brain barrier, which leads to interstitial cerebral edema, and
raised intracranial pressure [57, 58]. TNF-α is also produced by astrocytes and macrophages.
Its multiple pro-inflammatory properties include upregulation of class I and II MHC
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expression, upregulation of cellular adhesion molecules, increased permeability of the blood
brain barrier [59], and upregulation of inducible nitric oxide synthase (iNOS), leading to the
production of nitric oxide (NO) [60]. In addition to affecting virally-infected cells, the inflam-
matory response in the CNS may also damage non-infected cells to cause bystander cell death.
The elevated IL-6 and IL-4 responses observed in our patients support the hypothesis that
administration of IVIG modulates the immune response. Accepting cytokine responses are
complex, we chose to measure IL-6 and IL-4 because they have been used previously to give a
simple reflection of the balance of pro- to anti- inflammatory responses [61]. IVIG treatment
has previously been linked with both reduced and elevated levels of IL-6 among patients [62–
68]. Similarly, IVIG treatment has been related to increased IL-4 levels [69, 70]. Both IL-4 and
IL-6 participate in the development of antibody responses; IL-4 promotes B cell proliferation
and isotype switching and IL-6 induces differentiation of B cells into antibody secreting plasma
cells [71]. The modest increase in IL-4 and IL-6 could be consistent with augmentation of an
antibody response; therefore the increase in both antibody and pro-antibody producing cyto-
kines may reflect part of the same process [72]. The variation in response among patients with
different anti-JEV antibody statuses indicates the immune modulation by IVIG is highly
intricate.
Other mechanisms of IVIG induced cytokine production may involve the generation of im-
mune complexes of JEV antigen and IVIG derived antibody. In turn, these complexes may
stimulate monocytes to produce IL-6 via Fc-receptor interactions [73]. Other immunomodula-
tory factors (e.g., sCD4, sCD8, sHLA antigen) present in the IVIG could also induce cytokine
production [74, 75].
Because previous studies have shown IL6 is sometimes detected in IVIG [68, 76], we
checked the levels in our treatment batches and found that although there were low levels of
IL6, this was not enough to explain the elevated titre seen in our treated patients.
When JE is due to primary infection (i.e. first flavivirus infection) a quick and effective IgM
response occurs in the serum and CSF within few days, and attempts to isolate virus from ei-
ther sample are unlikely to be successful. [2] However, absence of IgM is associated with posi-
tive virus isolation from the CSF and a bad outcome [2]. When individuals have asymptomatic
JEV infection, antibody probably protects the host by restricting viral replication during the
viraemic phase, before the virus crosses the blood brain barrier [2]. Antibody may also limit
damage during established encephalitis by neutralizing extracellular virus and facilitating lysis
of infected cells by antibody-dependent cellular cytotoxicity.
A better understanding of immunological changes in JE and the effects of IVIG will be im-
portant for the further development of IVIG treatment [61]. Since this study showed our ap-
proach to be feasible, a larger study, with further close monitoring of adverse effects is
recommended. The question of efficacy will only be answered with a full phase III randomized
placebo-controlled trial.
There may be other wider implications of this study: the number of antibody-mediated
encephalitidies being identified is increasing and IVIG is a standard treatment option in these
cases [77, 78]. In addition, IVIG may have a role in other viral encephalitis as there is evidence
that damage caused is over and above that from direct viral infection alone [18, 79]. In most se-
ries of encephalitis patients the aetiology is unknown in the majority of cases, but is presumed
to be a mixture of microbial and immune mediated causes [78, 80]; whether IVIG may be a
suitable treatment for such patients is unclear. Our study provides important pilot data, but
further research is needed in this area.
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